Clinical Trials Logo

Cutaneous T-Cell Lymphoma clinical trials

View clinical trials related to Cutaneous T-Cell Lymphoma.

Filter by:

NCT ID: NCT01132989 Recruiting - Clinical trials for Cutaneous T Cell Lymphoma

Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

REvMM2009
Start date: May 2010
Phase: Phase 2
Study type: Interventional

Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite current treatment, necessitating chronic disease management. In addition, there needs to be greater emphasis on combination treatment, which correlates with increased response rate, more rapid onset of response, and decreased side effect profile compared to monotherapy. The goal for the use of Lenalidomide as an adjuvant treatment in patients with refractory cutaneous T cell lymphoma is to increase response rates, maintain a durable long-term response, relieve associated symptoms, and minimize toxic side effects.

NCT ID: NCT00779896 Recruiting - Clinical trials for Cutaneous T-Cell Lymphoma

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

Start date: October 2008
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 months.

NCT ID: NCT00177268 Recruiting - Atopic Dermatitis Clinical Trials

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

Start date: October 2004
Phase:
Study type: Observational

This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.